An official website of the United States government
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Trial Status: active
The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors
and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.
Inclusion Criteria
Participants must be ≥ 18 years of age.
Participants must have histologically confirmed diagnosis of a locally advanced, unresectable, or metastatic solid tumor malignancy.
Participants must have a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Participants must have a stable Eastern Cooperative Oncology Group Performance Status of 0 or 1.
For Part 2A only, participants must have CCNE1-amplified ovarian cancer
Exclusion Criteria
Participants must not have an active brain metastasis.
Participants must not have impaired cardiac function or clinically significant cardiac disease.
Participants must not have bleeding disorder or any history of clinically significant bleeding within the prior 3 months.
Participants must not have Grade ≥ 2 peripheral neuropathy.
Other protocol-defined Inclusion/Exclusion criteria apply.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06997029.
